3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a DecadeThe Motley Fool • 09/16/24
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementGlobeNewsWire • 09/03/24
Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare ConferenceGlobeNewsWire • 08/28/24
Royalty Pharma (RPRX) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/08/24
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q2 Earnings, Beyond Revenue and EPSZacks Investment Research • 08/05/24
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalGlobeNewsWire • 07/24/24
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024GlobeNewsWire • 07/19/24
Royalty Pharma (RPRX) Recently Broke Out Above the 50-Day Moving AverageZacks Investment Research • 07/17/24
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024InvestorPlace • 06/26/24
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/24
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionGlobeNewsWire • 05/28/24
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineGlobeNewsWire • 05/22/24